Pfizer announced this morning that the FDA has issued a Complete Response Letter for PF-05280014, a proposed trastuzumab biosimilar referencing Herceptin.
Pfizer announced this morning that the FDA has issued a Complete Response Letter (CRL) for PF-05280014, a proposed trastuzumab biosimilar referencing Herceptin.
The company says that the FDA highlighted the need for “additional technical information,” and that the agency did not request information related to safety or clinical data submitted in the Biologics License Application. Pfizer says that it is working closely with the FDA to address the letter’s contents and remains committed to developing the proposed product.
Pfizer presented positive results for PF-05280014 at the September 2017 meeting of the European Society for Medical Oncology; in the REFLECTIONS B327-02 study, the proposed biosimilar showed an equivalent objective response rate versus reference trastuzumab in patients receiving first-line treatment, in combination with paclitaxel, for HER2-positive metastatic breast cancer. The REFLECTIONS B327-04 study showed no clinically meaningful differences between the proposed biosimilar and the reference trastuzumab in terms of safety or immunogenicity, and noninferiority in pharmacokinetics.
Rejection of Pfizer’s trastuzumab candidate follows closely on the heels of another biosimilar trastuzumab’s rejection by the FDA; on April 5, Celltrion and Teva announced that the FDA had issued a CRL for their CT-P6, a decision that followed receipt a warning letter from the agency concerning manufacturing practices.
These 2 regulatory setbacks for biosimilar trastuzumab leave Mylan and Biocon’s Ogivri, which received the FDA’s approval 2017, as the only approved trastuzumab biosimilar in the United States. No launch date for Ogivri has yet been announced, however.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.